Latest Breaking News On - Gastrointestinal medical oncology - Page 1 : comparemela.com

Bile Duct Cancer Continues to Respond to Zanidatamab, Per Longer Follow-Up

Zanidatamab continued to lead to responses and improved overall survival in pretreated HER2-positive biliary tract cancer.

Novel targeted cancer therapies demonstrate activity and safety in metastatic solid tumors

Two early-phase clinical trials presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by researchers from The University of Texas MD Anderson Cancer Center demonstrate promising responses and safety profiles in heavily pretreated patients with advanced solid tumors.

Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024

/PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term follow-up results, including the first-ever overall survival (OS) findings,.

ASCO: New Targeted Therapies Prove Safe, Active in Metastatic Tumors

Dr Halperin on the FDA Approval of Lutetium Lu 177 Dotatate for Pediatric SSTR+ GEP-NETs